126 related articles for article (PubMed ID: 17716978)
1. Tamoxifen induction of CCAAT enhancer-binding protein alpha is required for tamoxifen-induced apoptosis.
Cheng J; Yu DV; Zhou JH; Shapiro DJ
J Biol Chem; 2007 Oct; 282(42):30535-43. PubMed ID: 17716978
[TBL] [Abstract][Full Text] [Related]
2. A functional serine 118 phosphorylation site in estrogen receptor-alpha is required for down-regulation of gene expression by 17beta-estradiol and 4-hydroxytamoxifen.
Cheng J; Zhang C; Shapiro DJ
Endocrinology; 2007 Oct; 148(10):4634-41. PubMed ID: 17615152
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death.
Obrero M; Yu DV; Shapiro DJ
J Biol Chem; 2002 Nov; 277(47):45695-703. PubMed ID: 12244117
[TBL] [Abstract][Full Text] [Related]
4. Annonacin induces cell cycle-dependent growth arrest and apoptosis in estrogen receptor-α-related pathways in MCF-7 cells.
Ko YM; Wu TY; Wu YC; Chang FR; Guh JY; Chuang LY
J Ethnopharmacol; 2011 Oct; 137(3):1283-90. PubMed ID: 21840388
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor alpha mediated induction of the transforming growth factor alpha gene by estradiol and 4-hydroxytamoxifen in MDA-MB-231 breast cancer cells.
MacGregor Schafer J; Liu H; Levenson AS; Horiguchi J; Chen Z; Jordan VC
J Steroid Biochem Mol Biol; 2001 Jul; 78(1):41-50. PubMed ID: 11530283
[TBL] [Abstract][Full Text] [Related]
6. Induction of UDP-glucuronosyltransferase 2B15 gene expression by the major active metabolites of tamoxifen, 4-hydroxytamoxifen and endoxifen, in breast cancer cells.
Chanawong A; Hu DG; Meech R; Mackenzie PI; McKinnon RA
Drug Metab Dispos; 2015 Jun; 43(6):889-97. PubMed ID: 25795461
[TBL] [Abstract][Full Text] [Related]
7. Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells.
Gao P; Wang X; Jin Y; Hu W; Duan Y; Shi A; Du Y; Song D; Yang M; Li S; Han B; Zhao G; Zhang H; Fan Z; Miao QR
Breast Cancer Res; 2018 Sep; 20(1):112. PubMed ID: 30208932
[TBL] [Abstract][Full Text] [Related]
8. Estrogen and the selective estrogen receptor modulator (SERM) protection against cell death in estrogen receptor alpha and beta expressing U2OS cells.
Kallio A; Guo T; Lamminen E; Seppänen J; Kangas L; Väänänen HK; Härkönen P
Mol Cell Endocrinol; 2008 Jul; 289(1-2):38-48. PubMed ID: 18455292
[TBL] [Abstract][Full Text] [Related]
9. Delayed and persistent ERK1/2 activation is required for 4-hydroxytamoxifen-induced cell death.
Zhou JH; Yu DV; Cheng J; Shapiro DJ
Steroids; 2007 Oct; 72(11-12):765-77. PubMed ID: 17714751
[TBL] [Abstract][Full Text] [Related]
10. Quercetin reverses tamoxifen resistance in breast cancer cells.
Wang H; Tao L; Qi K; Zhang H; Feng D; Wei W; Kong H; Chen T; Lin Q
J BUON; 2015; 20(3):707-13. PubMed ID: 26214621
[TBL] [Abstract][Full Text] [Related]
11. Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifen-resistant breast cancer cells.
Riggs KA; Wickramasinghe NS; Cochrum RK; Watts MB; Klinge CM
Cancer Res; 2006 Oct; 66(20):10188-98. PubMed ID: 17047084
[TBL] [Abstract][Full Text] [Related]
12. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells.
Vivacqua A; Bonofiglio D; Recchia AG; Musti AM; Picard D; Andò S; Maggiolini M
Mol Endocrinol; 2006 Mar; 20(3):631-46. PubMed ID: 16239258
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor alpha and beta heterodimers exert unique effects on estrogen- and tamoxifen-dependent gene expression in human U2OS osteosarcoma cells.
Monroe DG; Secreto FJ; Subramaniam M; Getz BJ; Khosla S; Spelsberg TC
Mol Endocrinol; 2005 Jun; 19(6):1555-68. PubMed ID: 15802376
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor beta activates the human retinoic acid receptor alpha-1 promoter in response to tamoxifen and other estrogen receptor antagonists, but not in response to estrogen.
Zou A; Marschke KB; Arnold KE; Berger EM; Fitzgerald P; Mais DE; Allegretto EA
Mol Endocrinol; 1999 Mar; 13(3):418-30. PubMed ID: 10076999
[TBL] [Abstract][Full Text] [Related]
15. 17 beta-estradiol- and 4-hydroxytamoxifen-induced transactivation in breast, endometrial and liver cancer cells is dependent on ER-subtype, cell and promoter context.
Castro-Rivera E; Safe S
J Steroid Biochem Mol Biol; 2003 Jan; 84(1):23-31. PubMed ID: 12648521
[TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor expression and estrogen receptor-independent cytotoxic effects of tamoxifen on malignant rhabdoid tumor cells in vitro.
Koshida S; Narita T; Kato H; Yoshida S; Taga T; Ohta S; Takeuchi Y
Jpn J Cancer Res; 2002 Dec; 93(12):1351-7. PubMed ID: 12495475
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen.
Bentrem D; Dardes R; Liu H; MacGregor-Schafer J; Zapf J; Jordan V
Endocrinology; 2001 Feb; 142(2):838-46. PubMed ID: 11159857
[TBL] [Abstract][Full Text] [Related]
18. Comparison of tamoxifen ligands on estrogen receptor interaction with estrogen response elements.
Klinge CM; Studinski-Jones AL; Kulakosky PC; Bambara RA; Hilf R
Mol Cell Endocrinol; 1998 Aug; 143(1-2):79-90. PubMed ID: 9806352
[TBL] [Abstract][Full Text] [Related]
19. A noncompetitive small molecule inhibitor of estrogen-regulated gene expression and breast cancer cell growth that enhances proteasome-dependent degradation of estrogen receptor {alpha}.
Kretzer NM; Cherian MT; Mao C; Aninye IO; Reynolds PD; Schiff R; Hergenrother PJ; Nordeen SK; Wilson EM; Shapiro DJ
J Biol Chem; 2010 Dec; 285(53):41863-73. PubMed ID: 21041310
[TBL] [Abstract][Full Text] [Related]
20. p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines.
Fernandez-Cuesta L; Anaganti S; Hainaut P; Olivier M
Int J Cancer; 2011 Apr; 128(8):1813-21. PubMed ID: 20549698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
